Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.
about
The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirusClinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?The interplay of reovirus with autophagyReovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors.Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction.Calpain inhibition protects against virus-induced apoptotic myocardial injury.Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.Computational prediction of the human-microbial oral interactome.Differences in the capacity of reovirus strains to induce apoptosis are determined by the viral attachment protein sigma 1Linkage between reovirus-induced apoptosis and inhibition of cellular DNA synthesis: role of the S1 and M2 genes.Mechanisms of reovirus-induced cell death and tissue injury: role of apoptosis and virus-induced perturbation of host-cell signaling and transcription factor activation.Gene therapeutics: the future of brain tumor therapy?Protective antibodies inhibit reovirus internalization and uncoating by intracellular proteases.Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infectionAdvances in oncolytic virus therapy for glioma.Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus nonstructural protein sigma1s is required for establishment of viremia and systemic dissemination.Reovirus-based therapy for cancer.Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinomaEffects of orally administered epidermal growth factor on enteropathogenic Escherichia coli infection in rabbits.The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway.The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.Reovirus as a novel oncolytic agent.Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer.Reovirus as an oncolytic agent against experimental human malignant gliomas.Current understanding of reovirus oncolysis mechanisms.Going (Reo)Viral: Factors Promoting Successful Reoviral Oncolytic Infection
P2860
Q24533256-F68A192C-1D52-4E86-9A8E-9FEFB0A762A8Q26750568-AAEA8225-658D-4CAC-BFBA-E6325C3FA6FFQ26775030-22CA7A45-EEB1-44EE-8E83-E443965E3C0DQ26851826-12E52C5B-51D5-4303-850F-AF9EEE0E1CE7Q33639727-6B782184-646D-430D-BE7B-22474DEA24B5Q33777888-31E2B5FA-885B-43AD-B591-39B951729A80Q33834904-51319436-2B5F-4F48-BA23-B23873B08938Q33923950-0AE8753E-DAA1-42B6-9B63-BD0849312B3CQ35104055-30887DB4-624E-4E04-AB11-AC44AE70485CQ35850820-72597967-3F8F-4584-8C8C-331AC32935C4Q35872484-CC7DDE18-B82F-4DE4-9696-A9B1639FF1F2Q36085535-18F8DF64-59FE-468C-8C94-4283092FBBF5Q36532106-B67D1CAE-2856-4EDF-9813-D2D267B6E2E9Q36636517-67753829-5780-43E7-AAE9-4465A2529CCFQ37285576-59F615DC-DD13-4686-88E9-3ACD4D55F420Q37287118-EE471682-6B06-4576-9B68-9BBD2AD87471Q37347236-3140D442-D964-4250-AE83-EE6DA4942303Q37414112-E5E25B2D-1C58-49A8-8F07-5CC1BE7CF621Q37519640-F664BAF9-C8A6-4D96-8E4A-2A99AFAFD00BQ38229052-DEFF5880-0C96-4FF9-93FF-F6A712839F92Q38360781-EE16CC3A-C19D-434C-B65F-BE41EA27F64BQ38885144-360CCB3C-CF97-40C5-80E1-BD1FF3E52E60Q39573285-7ED7C533-6548-4E85-BF78-FBAA8D93C6CCQ39703425-ED3ED930-1848-4384-849C-5836EB6C7ED0Q39751677-9E7E7BF2-4201-4380-A96B-5484CF17F121Q39873213-AFA3A50B-2630-4A47-8E93-5DBF323C4FF6Q40365039-5C3D0F79-317B-4CDE-997C-08EE39489667Q40515050-F7473505-CFCC-4487-9008-440482784E6BQ43646730-CB768760-AF08-4576-9C14-14834A6F59AAQ55427397-181F4BE7-869F-417A-9513-B7615EB726E7Q56986466-56AEFAB0-D89D-42BA-8CFF-4A7898D0CFA9
P2860
Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency.
description
1993 nî lūn-bûn
@nan
1993 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Evidence that the epidermal gr ...... reovirus infection efficiency.
@ast
Evidence that the epidermal gr ...... reovirus infection efficiency.
@en
Evidence that the epidermal gr ...... reovirus infection efficiency.
@nl
type
label
Evidence that the epidermal gr ...... reovirus infection efficiency.
@ast
Evidence that the epidermal gr ...... reovirus infection efficiency.
@en
Evidence that the epidermal gr ...... reovirus infection efficiency.
@nl
prefLabel
Evidence that the epidermal gr ...... reovirus infection efficiency.
@ast
Evidence that the epidermal gr ...... reovirus infection efficiency.
@en
Evidence that the epidermal gr ...... reovirus infection efficiency.
@nl
P2093
P356
P1433
P1476
Evidence that the epidermal gr ...... reovirus infection efficiency.
@en
P2093
P304
P356
10.1006/VIRO.1993.1602
P407
P577
1993-11-01T00:00:00Z